Search | Clinical Trials Finder

Conditions: Atopic Dermatitis, Alopecia Areata
Interventions: Abrocitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Genital Herpes Simplex Type 2
Interventions: VCL-HB01, VCL-HM01, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Head Injury, Traumatic Brain Injury (TBI), Photosensitivity, Photophobia
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acne Vulgaris
Interventions: adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel); Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Fremont, California • Miami, Florida • Miramar, Florida + 5 more

Conditions: Psoriasis
Interventions: CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo; Drug
Lead sponsor: Janssen Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more

Conditions: Alopecia Areata
Interventions: Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10), Restylane; Drug · Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: Olaparib, Carboplatin, Anthracycline, Cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: New York, New York • Stony Brook, New York

Conditions: Breast Cancer
Interventions: Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 3,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 393
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more

Conditions: Community-Acquired Staphylococcus Aureus
Interventions: Routine Measures Group, Bleach Bath Group (Bleach plus routine measures); Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 18 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Obesity, Overweight
Interventions: NNC0487-0111, Placebo (NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging; Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions: Nitroglycerin, Topical AmphiMatrix; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 15 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more

Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Post-traumatic Arthritis
Interventions: Ascension® MCP Finger Implant; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Bloomington, Indiana • Carmel, Indiana + 5 more

Conditions: Breast Cancer
Interventions: Cholecalciferol; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Breast Cancer, Hot Flashes
Interventions: gabapentin, antidepressant; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 162
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Augusta, Georgia + 101 more

Conditions: Acne Vulgaris
Interventions: Study of humoral immunity; Diagnostic Test
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions: Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention; Dietary Supplement · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plaque Psoriasis
Interventions: AUR101, Placebo; Drug
Lead sponsor: Aurigene Discovery Technologies Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 25
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 19 more

Conditions: Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions: MQX-503; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Timeline: 2006
U.S. locations: 1
States / cities: Renton, Washington

Conditions: Pemphigus Vulgaris
Interventions: PI-0824; Drug
Lead sponsor: Peptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: San Francisco, California • Baltimore, Maryland • Salisbury, Massachusetts + 5 more

Conditions: Ectropion, Skin Neoplasms
Interventions: 5-Fluorouracil, Normal saline; Drug · Other
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Endometrial Cancer
Interventions: HLA vaginal gel (HyaloGYN®),, questionnaires; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer
Interventions: TT-00420; Drug
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions: Nivolumab, NKTR-214; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Little Rock, Arkansas • St Louis, Missouri

Search by objective public record fields.

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis

Vitamin D Supplementation in Women With DCIS and/or LCIS

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

Acne Vulgaris Related Microbiology and Serology

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Safety Study of PI-0824 to Treat Pemphigus Vulgaris

5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts

Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health

Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer